🧾 What This Document Is — And Why You're Reading It

This is a PRELIMINARY PROXY STATEMENT (PRE 14A) for Allarity Therapeutics, Inc. (ALLR). Think of it as an "information packet" the company sends to shareholders before their big annual meeting. Its job is to explain everything shareholders will vote on and provide the details they need to make informed decisions.

👉 Why it matters: This isn't a report on past performance; it's a forward-looking document about governance and key decisions. The company is asking its owners (shareholders) for their input on important matters like electing directors, approving plans, and authorizing future actions.

The Big Picture: The annual meeting will be held virtually on Friday, June 26, 2026, at 10:00 a.m. ET. If you owned shares as of May 7, 2026 (the "Record Date"), you get to vote.

🏢 What The Company Does — In Simple Terms

Allarity Therapeutics is a clinical-stage biopharmaceutical company. That means they are developing new drugs but haven't brought one to market yet. Their main focus is on oncology (cancer treatments).

They have a proprietary technology called the DRP® (Drug Response Predictor) platform. This is essentially a companion diagnostic tool. Imagine it like this: instead of giving every patient the same cancer drug, they use the DRP® test to predict which patients are most likely to respond to a specific drug. This is the heart of precision medicine.

👉 Why it matters: As a small, development-stage biotech, Allarity is burning cash to fund research and trials. This means every dollar counts, shareholder approval for financing is critical, and attracting/retaining talented scientists and executives is a top priority. You'll see this theme throughout the proposals.

💰 Financial Highlights — The Numbers That Count

While this isn't an earnings report, some key financial figures are embedded in the proposals:

Audit Fees: The company paid its auditor, Wolf & Company, P.C., $499,750 in 2025 (up from $408,225 in 2024). This is the cost for ensuring their financial statements are trustworthy.
Equity Plan at Play: The company wants to add 500,000 new shares to its employee stock plan (Proposal 3), increasing the total reserved shares from 1,521,990 to 2,021,990.
Funding Mechanism: They have an agreement with an investor, Tumim Stone Capital, that could provide up to $6,000,000 by selling shares (Proposal 5). The exact number of shares isn't fixed because the price changes daily.

🚀 Key Moves — The 7 Things Shareholders Are Voting On

The core of this document is a list of seven proposals. Here’s what’s really happening:

Elect a Director (Proposal 1): Vote to keep Jesper Hoiland on the Board until 2029. He's an experienced biotech commercialization executive.
Rubber-Stamp the Auditor (Proposal 2): Ratify the choice of Wolf & Company, P.C. as the independent accounting firm for 2026. This is standard.
Expand the Employee Stock Pool (Proposal 3): Approve adding 500,000 shares to the 2021 Equity Incentive Plan. This is for attracting and keeping talent.
Say-on-Pay Vote (Proposal 4): Take a non-binding vote on executive compensation. It's advisory but signals shareholder sentiment.
Greenlight a Funding Facility (Proposal 5): This is crucial. Approve issuing potentially more than 19.99% of the company's shares to Tumim Stone Capital under a $6M equity line. Nasdaq rules require shareholder approval for such a large potential dilution.
Limit Officer Liability (Proposal 6): Amend the corporate charter to protect certain officers from personal lawsuits for breaches of the duty of care (with major exceptions for misconduct).
Allow a Do-Over (Proposal 7): Authorize the board to adjourn (pause) the meeting if needed to get more votes for the other proposals.

📦 Financial Position & Strategy — What These Proposals Signal

These proposals reveal a lot about the company's strategic posture:

Talent is Key (Proposal 3): Expanding the stock plan shows they rely heavily on equity to pay and incentivize their small team of 7 employees and directors. They need this tool to compete for talent.
Dilution is a Real Concern (Proposal 5): The equity line with Tumim Stone is a flexible but potentially expensive source of cash. Approval means significant dilution for existing shareholders is possible. The board strongly recommends it, signaling they believe this access to capital is necessary for operations.
Protecting Management (Proposal 6): This move to shield officers from certain lawsuits is about risk management and making executive positions more attractive.

🔮 What's Next — The Path Forward

If all proposals pass, Allarity will:

Have its confirmed Board and auditor.
Have a larger pool of stock options to grant employees.
Have shareholder blessing to potentially issue a large chunk of stock to fund operations.
Have implemented a legal protection for its officers.

The company's next major steps will be advancing its DRP®-guided cancer drug candidates through clinical trials, using the capital from mechanisms like the equity line to fund that expensive process.

⚖️ Big Picture — Strengths (👍) and Risks (⚠️)

👍 Strengths: Focused on a hot area of medicine (precision oncology). Has a novel companion diagnostic platform. Board and management have deep biotech experience. Uses virtual meetings for accessibility and cost savings.
⚠️ Risks: High burn rate typical of clinical-stage biotech. Constant need for dilutive financing (as shown by Proposal 5). Drug development is risky and uncertain; success is not guaranteed. Small size makes it vulnerable.

🧠 The Analogy

Allarity is like a small, specialized research lab with a promising but unproven prototype technology. To keep the lab lights on and pay its star scientists (Proposal 3), it needs to keep buying expensive equipment and chemicals. It has a flexible line of credit with an investor (Proposal 5), but using it means giving that investor a bigger and bigger share of the lab itself. The shareholders are being asked, "Do you trust the lab directors (Proposal 1) and their plan enough to let them keep funding the research this way?"

🧩 Final Takeaway

This is a routine but critical annual governance meeting for a small, cash-consuming biotech. The most important item is Proposal 5, which seeks approval for a potentially major stock issuance to fund the company's operations. Shareholders are essentially voting on whether they support the board's current strategy for financing the long, expensive journey of drug development.

ALLR Shareholders to Vote on $6M Equity Line Proposal